Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial

Bile acid sequestrants (BAS) lower plasma low density lipoprotein levels and improve glycemic control. Colestimide, a BAS, has been claimed by computed tomography to reduce liver fat. Therefore, we examined the efficacy of colesevelam, a potent BAS, to decrease liver fat in patients with biopsy-proven nonalcoholic steatohepatitis (NASH). Liver fat was measured by a novel magnetic resonance imaging (MRI) technique, the proton-density-fat-fraction (PDFF), as well as by conventional MR spectroscopy (MRS). Fifty patients with biopsy-proven NASH were randomly assigned to either colesevelam 3.75 g/day orally or placebo for 24 weeks. The primary outcome was change in liver fat as measured by MRI-PDFF in colocalized regions of interest within each of the nine liver segments. Compared with placebo, colesevelam increased liver fat by MRI-PDFF in all nine segments of the liver with a mean difference of 5.6% (P = 0.002). We cross-validated the MRI-PDFF-determined fat content with that assessed by colocalized MRS; the latter showed a mean difference of 4.9% (P = 0.014) in liver fat between the colesevelam and the placebo arms. MRI-PDFF correlated strongly with MRS-determined hepatic fat content (r(2) = 0.96, P < 0.0001). Liver biopsy assessment of steatosis, cellular injury, and lobular inflammation did not detect any effect of treatment. Conclusion: Colesevelam increases liver fat in patients with NASH as assessed by MRI as well as MRS without significant changes seen on histology. Thus, MRI and MRS may be better than histology to detect longitudinal changes in hepatic fat in NASH. Underlying mechanisms and whether the small MR-detected increase in liver fat has clinical consequences is not known. (HEPATOLOGY 2012;56:922-932).     

Longitudinal correlations between MRE,MRI-PDFF,and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

1. Download high-res image (67KB)
2. Download full-size image

     

Thigh-length versus knee-length compression stockings for deep vein thrombosis prophylaxis in the inpatient setting

Deep vein thrombosis may be a complication of extended length hospital stays. Immobilized patients, such as patients in the postoperative period, are at particularly high risk of developing a deep vein thrombosis, which can be associated with high levels of morbidity and mortality. Due to this, prevention of deep vein thrombosis is of great importance in the inpatient setting. Compression stockings have proven to play an important role in prophylaxis and may be used in their knee-length or thigh-length variety. Although randomized trials have studied the efficacy of both varieties in prevention of deep vein thrombosis, selection is often made without regard to evidence. This meta-analysis pools the findings of current studies comparing knee-length and thigh-length compression stockings for deep vein thrombosis prophylaxis. A fixed effects model was used for this study with a two-sided α-error less than 0.05 considered to be statistically significant. When both varieties of compression stockings are compared, thigh-length stockings offer a risk reduction in deep vein thrombosis development when compared with knee-length (odds ratio 1.197, confidence interval 0.983-1.458). This, however, is an insignificant finding. This analysis concludes that current data does not favor either thigh-length or knee-length compression stockings when it comes to prophylaxis of deep vein thrombosis.     

Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis

Abdominal Radiology - To determine the inter-reader agreement of magnetic resonance imaging proton density fat fraction (PDFF) and its longitudinal change in a clinical trial of adults with...